Please note that the Company does not update, correct or revise news releases after they have been issued. For the most current information about the Company, please refer to the most recent releases.

FOR RELEASE 6/22/2009, Monday

Bausch & Lomb Canada Introduces PrLotemax™ and PrAlrex®

TORONTO — Lotemax™ (loteprednol etabonate 0.5%) and Alrex® (loteprednol etabonate 0.2%) are now available by prescription in Canada.  Canadians can now benefit from the proven efficacy and safety record of these two unique ocular steroids used by millions of patients for over 10 years.1

Lotemax, indicated for the treatment of post-operative inflammation following cataract surgery, is the number one branded ocular steroid in the U.S.2  Alrex is indicated for temporary, short-term relief of the signs and symptoms of seasonal allergic conjunctivitis (SAC).

Both Lotemax and Alrex are based on the loteprednol etabonate molecule, which is an ester-based molecule.  It is structurally similar to other corticosteroids, however, the number 20 position ketone is replaced with an ester group, which in turn gives both products unique properties and benefits.1

# # #

About Bausch & Lomb
Bausch & Lomb is dedicated to bringing visionary ideas to eye health. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. The Bausch & Lomb name is one of the best-known and most respected healthcare brands in the world. Founded in 1853, the company is headquartered in Rochester, N.Y., and employs more than 10,000 people worldwide. Its products are available in more than 100 countries. More information is available at



1.       Lotemax™ and Alrex® Product Monographs
2.       Data on File

Actions: E-mail | Permalink |